Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
264 people get HITK articles and Market Currents by email alert.
Get email alerts on HITK »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
Business Wire (May 9, 2013)
-
Business Wire (Apr 29, 2013)
-
Business Wire (Mar 7, 2013)
-
Business Wire (Mar 4, 2013)
-
Business Wire (Feb 26, 2013)
-
-
Business Wire (Dec 11, 2012)
-
Business Wire (Dec 6, 2012)
-
Business Wire (Nov 30, 2012)
-
-
Business Wire (Nov 29, 2012)
-
-
Business Wire (Sep 5, 2012)
-
Business Wire (Sep 4, 2012)
-
7 Liquid Small-Cap Healthcare Stocks Rated Buy Or Better By AnalystsZetaKap • Tue, Aug 28, 2012
To learn more about Seeking Alpha Pro, click here.
-
-
-
7 Liquid Small-Cap Healthcare Stocks Rated Buy Or Better By AnalystsZetaKap • Tue, Aug 28, 2012
-
-
-
3 Drugmakers Deeply Undervalued By The Graham NumberKapitall • Thu, Jul 19, 2012
-
-
-
6 Profitable Small Cap Healthcare Stocks Holding Large Cash ReservesZetaKap • Fri, Jun 22, 2012
-
6 Highly Liquid Small-Caps Undervalued By The Graham NumberKapitall • Tue, Jun 5, 2012
-
Cinderellas Abound In Hoops ... And The MarketJohn Reese • Wed, Mar 21, 2012 -
-
-
-
18 Healthcare Stocks With A History Of Earnings SurprisesKapitall • Wed, Jan 18, 2012
-
Profiting From Half-Hearted Analyst CoverageMarc Gerstein • Wed, Dec 7, 2011 -
-
20 Healthcare Stocks With Strong Sales TrendsKapitall • Thu, Dec 1, 2011
-
-
2 Bull-Run Stocks With Optionable StrategiesJohn Mylant • Wed, Nov 16, 2011
-
Business Wire (May 9, 2013)
-
Business Wire (Apr 29, 2013)
-
Business Wire (Mar 7, 2013)
-
Business Wire (Mar 4, 2013)
-
Business Wire (Feb 26, 2013)
-
Business Wire (Dec 11, 2012)
-
Business Wire (Dec 6, 2012)
-
Business Wire (Nov 30, 2012)
-
Business Wire (Nov 29, 2012)
-
at MarketWatch.com (Sep 5, 2012)
-
Business Wire (Sep 5, 2012)
-
Business Wire (Sep 4, 2012)
-
Business Wire (Aug 13, 2012)
-
at CNBC.com (Jul 16, 2012)
-
at MarketWatch.com (Jul 10, 2012)
-
Business Wire (Jul 5, 2012)
-
Business Wire (Jun 4, 2012)
-
Business Wire (Jun 1, 2012)
HITK vs. ETF Alternatives
Company Description
Hi-Tech Pharmacal Co. Inc., a Delaware corporation, incorporated in April 1982, is a specialty manufacturer and marketer of prescription, over-the-counter and nutritional products.
We develop, manufacture and market products in three categories – generics, prescription brands and over the... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, March 7, 7:14 AM Hi-Tech Pharmacal (HITK): Q4 EPS of $0.43. Revenue of $64.3M beats by $3.85M. (PR) Comment! [Earnings, Breaking News, Healthcare]
-
Thursday, December 6, 2012, 12:45 PM
Midday top 10 gainers: BSDM +28%. EPHC +27%. MBLX +22%. INPH +18%. NVGN +18%. UEPS +17%. HITK +13%. CZR +11%. MITK +11%. CVO +11%.
Midday top 10 Losers: ENZN -30%. TIGR -19%. SCMR -17%. NBY -16%. LFVN -14%. WEBM -14%. SNFCA -13%. KBW -13%. VRA -12%. HF -11%. Comment! [On the Move] - Thursday, December 6, 2012, 7:09 AM Hi-Tech Pharmacal (HITK): FQ2 EPS of $0.66 beats by $0.13. Revenue of $57.5M beats by $2.5M. (PR) Comment! [Earnings, Healthcare]
- Friday, November 30, 2012, 7:26 AM Hi-Tech Pharmacal (HITK) declares special dividend of $1.50/share quarterly dividend. For shareholders of record Dec 13. Payable Dec 28. Ex-div date Dec 11. (PR) Comment! [Dividends]
-
Thursday, November 29, 2012, 12:45 PM
Midday top 10 gainers: HGSH +48%. ACUR +46%. PBM +42%. BLOX +36%. OCZ +24%. THQI +23%. AXR +22%. CARV +21%. TELK +20%. OBCI +16%.
Midday top 10 Losers: LQDT -17%. VRML -13%. ATEA -12%. LZB -11%. HITK -10%. KSS -9%. LAS -9%. BKS -9%. ABCD -8%. PIP -7%. Comment! [On the Move] - Wednesday, September 5, 2012, 2:14 PM Hi-Tech Pharmacal (HITK -12%) gets slammed after missing on its FQ1 earlier this morning. Net earnings fell 56% as lower average prices for its generic nasal spray contributed to its first revenue decline in two years. The specialty pharmaceutical company's bottom line also was hurt by increased expenses for sales and advertising, as well as R&D at its generic business. Comment! [Earnings, On the Move, Healthcare]
-
Wednesday, September 5, 2012, 9:10 AM
Premarket gainers: GWRE +14%. PSTI +11%. GDOT +9%. SWY +6%. SRPT +6%.
Losers: HITK -10%. AUQ -9%. TGP -5%. 1 Comment [On the Move] - Wednesday, September 5, 2012, 7:12 AM Hi-Tech Pharmacal (HITK): FQ1 EPS of $0.44 misses by $0.24. Revenue of $52M (-7% Y/Y) misses by $5M. (PR) Comment! [Earnings]
- Tuesday, July 10, 2012, 7:08 AM Hi-Tech Pharmacal (HITK): Q4 EPS of $0.73 misses by $0.05. Revenue of $61.3M (+7.2% Y/Y) beats by $4M. (PR) Comment! [Earnings, Healthcare]
- Wednesday, March 21, 2012, 10:54 AM Borrowing a bit from March Madness basketball lexicon, John Reese finds 5 stocks he calls his "Cinderellas" to outperform after running sub-$500M market cap companies through growth and valuation filters. Picks to make a run: BODY, KAI, HITK, KWR, ALG. Comment! [Quick Ideas]
- Thursday, March 8, 2012, 9:13 AM Hi-Tech Pharmacal (HITK) -6.9% premarket after missing its FQ3 earnings number and acquiring several homeopathic branded nasal spray products including Sinus Buster and Allergy Buster from privately-held Dynova Laboratories. Comment! [Healthcare, On the Move]
- Thursday, March 8, 2012, 7:18 AM Hi-Tech Pharmacal (HITK): FQ3 EPS of $0.79 misses by $0.08. Revenue of $55.6M (+11.9% Y/Y) in-line. (PR) Comment! [Earnings, Healthcare]
- Wednesday, February 29, 2012, 8:15 AM Hi-Tech (HITK) lands final FDA approval for its seizure treatment Levetiracetam. The drug is a generic version of UCB Pharma’s Keppra oral solution which had combined brand and generic sales of $62M in 2011. Shares +1.3% premarket. Comment! [Healthcare, On the Move]
- Tuesday, January 10, 2012, 2:03 PM Shares of Hi-Tech Pharmacal (HITK -18.1%) fall off sharply after rival Wockhardt says it landed FDA approval for a generic copy of GlaxoSmithKline's Flonase nasal spray in a development that could dampen sales of the firm's own generic offering. 1 Comment [On the Move, Healthcare]
- Thursday, December 1, 2011, 9:26 AM Four new names on Daniel Miller and Jason Robinson's Wall Street Bean Screen for December, exhibiting fundamental strength: TNH, FCFS, TEO, MSFT. Their overall top five: HITK, CEO, RES, EZPW, GRMN. Comment! [Quick Ideas]
- Wednesday, September 7, 2011, 11:36 AM The biotech industry looks ripe for more gains after posting a second consecutive year of profits and seeing M&A activity heat up, says Karvy Global Services. Crunching the numbers reveals 8 stocks with implied upside potential based on quarterly results and analyst recommendations. Picks: HITK, CELG, DNDN, WX, TEVA, ILMN, CRL, BIIB. Comment! [Quick Ideas]
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
1980XLS-2.0
HITK has been a nice place to hide for the last couple days. Took profits this am for nice gains - View all 1 replies
-
briandiplacido: I wonder how many years it took you to develop that list of "good places to hide on -200 point days" list?
-
Michael Bryant
I think Hi Tech Pharmacal (HITK) is really cheap at a trailing PE of 9. http://yhoo.it/uXOIdg - View all 0 replies
-
- View all 0 replies
-
Master Che
HITK: Bias: Bullish Down to 29.24 Strong buying support at 30.30 Not reaching 29.24 then up to 52.25 Within 11 months it will reach 56.32 - View all 0 replies
-
- View all 0 replies
-
Michael Bryant
Watch NutriSystem (NTRI), Athersys (ATHX), Hi-Tech Pharmacal (HITK), & Mercer (MERC), some of the few stocks that rose yesterday. - View all 0 replies
-
- View all 2 replies
-
1980XLS-2.0: Was, now it's not. Hayes pick, down nealy 10% per my comments before the bell.
-
Michael Bryant: And that is another reason it is a good buy: it fell for almost no reason.
LATEST REPLIES
-
1980XLS-2.0
HITK has been a nice place to hide for the last couple days. Took profits this am for nice gains - View all 1 replies
-
briandiplacido: I wonder how many years it took you to develop that list of "good places to hide on -200 point days" list?
-
- View all 2 replies
-
1980XLS-2.0: Was, now it's not. Hayes pick, down nealy 10% per my comments before the bell.
-
Michael Bryant: And that is another reason it is a good buy: it fell for almost no reason.
-
- View all 5 replies
-
1980XLS-2.0: Defensive sector may limit much more upside, while people start chasing Beta however.
-
1980XLS-2.0: stock perferming as I suspected it may have. Selling the news and rotation into cyclical beta